Samsung Biologics KRW 3 Trillion Rights Offering
Analysis based on 6 articles · First reported Jul 20, 2026 · Last updated Aug 28, 2026
The rights offering is expected to dilute existing shareholders by about 4.9%, leading to a near 7% drop in Samsung Biologics — Samsung Biologics America shares. The capital raise will fund the acquisition of PolyPeptide Group and capacity expansion, potentially strengthening Samsung Biologics — Samsung Biologics America' position as a top-tier CDMO and supporting long-term growth.
Samsung Biologics — Samsung Biologics America announced a rights offering to raise approximately KRW 3 trillion to fund its three-dimensional growth strategy. The proceeds will be allocated about KRW 2.71 trillion toward the planned acquisition of PolyPeptide Group, with the remaining KRW 290 billion for expanding Bio Campus II. The offering consists of about 2.27 million new shares at KRW 1,322,000 each, a 15% discount to the reference price, representing about 4.90% of market capitalization. The acquisition of PolyPeptide Group, announced in July for CHF 1.46 billion, will broaden Samsung Biologics — Samsung Biologics America' portfolio into peptide-based therapeutics. The company also plans to bring Plants 6-8 online at Bio Campus II, increasing global manufacturing capacity to 1,385,000 liters by 2032. The rights offering will be made pro-rata to existing shareholders, with 20% allocated to the employee stock ownership association. The registration statement takes effect September 30, with subscription periods in November and listing targeted for November 30. Samsung Biologics — Samsung Biologics America shares fell nearly 7% following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard